VC-backed Histogenics goes public

By Iris Dorbian — 12 months ago

Waltham, Mass.-based Histogenics Corp., a regenerative medicine developer, has debuted its IPO after pricing its 5.9 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “HSGX.” Cowen and Co., Needham & Co. and Canaccord Genuity are the lead underwriters. Histogenics’ backers include Sofinnova Ventures, Split Rock Partners and Altima Partners.


Histogenics Lines up Big-Name Life Sci VCs for Mega A-Round

By Jonathan Marino — 3 years ago

Waltham, Mass.-based regenerative medicine developer Histogenics Corp. wrapped up a $49 million Series A round, the company revealed Tuesday. Sofinnova Ventures led the big round, and was joined by a litany of backers: Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. invested for the first time, and were joined by ProChon Holdings BV, […]